Daprodustat
- Generic Name
- Daprodustat
- Brand Names
- Jesduvroq
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N3O6
- CAS Number
- 960539-70-2
- Unique Ingredient Identifier
- JVR38ZM64B
- Background
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces e...
- Indication
用于治疗由慢性肾脏病（CKD）导致的肾性贫血，包括透析和非透析CKD患者。
- Associated Conditions
- Anemia
- Associated Therapies
- -
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- USRC Kidney Research
- Target Recruit Count
- 161
- Registration Number
- NCT05951192
- Locations
- 🇺🇸
USRC Kidney Research, Lone Tree, Colorado, United States
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT05682326
- Locations
- 🇰🇷
GSK Investigational Site, Yangsan Gyeongnam, Korea, Republic of
Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 259
- Registration Number
- NCT04640311
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03457701
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03446612
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT03029247
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT03029208
- Locations
- 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2964
- Registration Number
- NCT02879305
- Locations
- 🇬🇧
GSK Investigational Site, Salford, United Kingdom
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3872
- Registration Number
- NCT02876835
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.